Smokers run increased risk of developing anti-natalizumab antibodies

Hedström, AK; Alfredsson, Lars; Ryner, Malin; Fogdell‐Hahn, Anna; Hillert, Jan; Olsson, Tomas

doi:10.1177/1352458513515086

Cited by 40 publications

(28 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cigarette smoking has been confirmed to be an environmental/life-style factor that increases the susceptibility to develop MS [54][55][56], and there is also a possible correlation between smoking and disease progression [174,175]. Interestingly; smoking has also been shown to influence the risk for MS patients to develop ADA against both IFNβ [136,137] and natalizumab [176]. These findings suggest that the lung is an immune-competent organ, which not only impact disease susceptibility but also influences the response to therapy.…”

Section: Discussionmentioning

confidence: 98%

Characterization of anti-natalizumab antibodies in multiple sclerosis patients

et al. 2012

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Characterization of anti-natalizumab antibodies in multiple sclerosis patients

et al. 2012

Self Cite

View full text Add to dashboard Cite

show abstract

“…IMSE -Since the launch of Tysabri Ò (natalizumab, Biogen, Cambridge, MA, USA) in 2006, Swedish MS patients prescribed newly licensed Table 1 The most important parameters of the Swedish MS registry, of which some are mandatory and others recommended or optional, depending on physician's preference or participation in local or national focused follow-up projects such as IMSE (see text). Typically physicians tend to enter data that they find useful for summarizing patient information or for statistics (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21). The combined access to both lifestyle and extensive genotyping available on patients recruited to the IMSE, EIMS, and GEMS studies offers a unique possibility to investigate whether genetic and environmental risk factors interact in predisposing to MS.…”

Section: Msmentioning

confidence: 99%

The Swedish MS registry – clinical support tool and scientific resource

2015

View full text Add to dashboard Cite

The Swedish MS registry (SMSreg) is designed to assure quality health care for patients with multiple sclerosis (MS). It has been active since 2001 and web-based since 2004. It runs on government funding only and is used in all Swedish neurology departments. The SMSreg currently includes data on 14,500 of Sweden's estimated 17,500 prevalent patients with MS. One important function of SMSreg, to which participation is voluntary, is to serve as a tool for decision support and to provide an easy overview of the patient information needed at clinical visits. This is its core feature and explains why the majority of Swedish MS specialists contribute data. Another success factor for SMSreg is that entered data can be readily accessed, either through a query function into Excel format or through a set of predesigned tables and diagrams in which parameters can be selected. Recent development includes a portal allowing patients to view a summary of their registered data and to report a set of patient-reported outcomes. SMSreg data have been used in close to 100 published scientific reports. Current projects include an incidence cohort (EIMS), post-marketing cohorts of patients on novel disease-modifying drugs (IMSE), and a prevalence cohort (GEMS). As these studies combine physical sampling and questionnaire data with clinical documentation and possible linkage to other public registries, together they provide an excellent platform for integrated MS research.

show abstract

“…Smoking is a risk factor for MS and stronger if combined with the well‐known HLA associations. Smoking is also a risk factor for developing ADA, both in IFN‐ β ‐ and in natalizumab‐treated MS patients . Understanding the role the lung, or in these cases the smoke‐irritated lung, has in regulating the immune system during autoimmune reactions may inform on the mechanisms underlying ADA induction.…”

Section: Risk Factors For Ada In Msmentioning

confidence: 99%

Antidrug Antibodies: B Cell Immunity Against Therapy

Fogdell‐Hahn

2015

Scand J Immunol

View full text Add to dashboard Cite

Chronic inflammatory diseases are now treated with a range of different biopharmaceuticals, often requiring lifelong parenteral administrations. This exposure to drugs is unnatural and can trigger the immune system and result in the formation of antidrug antibodies. Drug-specific antibodies will, if of sufficiently high titre and affinity, block the intended effect of the drug, increase its clearance and make continued treatment worthless. We expect the immune system to react towards therapies against which tolerance has never been established, which is the case for factor VIII treatment in patients with haemophilia A. However, even biopharmaceutical molecules that we should be tolerant against can elicit antidrug antibodies, for instance in treatment of multiple sclerosis patients with recombinant human interferon-beta. Possible immunological mechanisms behind the breaking of tolerance against drugs, the impact this has on continuous treatment success, clinical practice and drug development, will be discussed in this review.

show abstract

Smokers run increased risk of developing anti-natalizumab antibodies

Abstract: The finding strengthens our hypothesis of the lungs as immune-reactive organs on irritation in relation to autoimmune responses, and may also be of clinical relevance since antibodies against natalizumab abrogate the therapeutic effect of the treatment.

Cited by 40 publications

References 13 publications

Characterization of anti-natalizumab antibodies in multiple sclerosis patients

Characterization of anti-natalizumab antibodies in multiple sclerosis patients

The Swedish MS registry – clinical support tool and scientific resource

Antidrug Antibodies: B Cell Immunity Against Therapy

Contact Info

Product

Resources

About